Published
2023-11-10
Section
Articles
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
New approaches to the treatment of patients with an overactive bladder and non-obstructive urge urinary incontinence
Kasimov S.S
Tashkent Medical Academy, Uzbekistan, Tashkent.
Navruzov E.R
Tashkent Medical Academy, Uzbekistan, Tashkent. State institution "Republican Specialized Scientific and Practical Medical Center of Urology", Uzbekistan, Tashkent.
Keywords: oxybutynin, M-anticholinergic agent, overactive bladder, microcirculation
Abstract
Overactive bladder (OAB) occurs in 20% of patients with various urinary disorders, while urge urinary incontinence is detected among a third of these patients. The goal of the work was to improve the results of treatment of women suffering from OAB with urge urinary incontinence and non-obstructive urination, by using a combination of drugs - an α1-adrenergic blocker and an M-anticholinergic blocker; study of the relationship between clinical and urodynamic manifestations of the disease. The state of microcirculation of the bladder mucosa was also studied before and after treatment. We examined and treated 40 women from 17 to 69 years old with a disease duration of one to 20 years. The patients were prescribed a combination of the α1-adrenergic blocker tamsulosin 0.4 mg at night and the M-anticholinergic blocker oxybutynin 5 mg in the morning daily for a month. After treatment, according to uroflowmetry and cystometry, the time of urination was shortened, the volume of urination increased and the maximum volumetric flow rate of urine increased; in addition, the cystometric capacity increased; involuntary detrusor contractions during the bladder filling phase (spontaneous or provoked) became fewer or were absent altogether. According to the results of ultrasound examination, the volume of residual urine decreased. According to the results of the treatment, a clinical effect was noted in 29 (73%) patients, urinary incontinence – in only 6 (15%) patients.
References
Gorilovsky L.M., Lakhno D.A. Overactive bladder. RMJ. 2005; 25:1691.
Pushkar D.Yu., Shaveleva O.B. Drug treatment of imperative urinary disorders. Pharmateka. 2002; 10:9–16.
Krivoborodov G.G., Mazo E.B. Overactive bladder. Veche. 2003;192.
Davila G.W., Neimark M. The overactive bladder: prevalence and effects on quality of life. Clin. Obstet. Gynecol. 2002; 45: 173–181.
Mazo E.B., Shkolnikov M.E., Moiseev P.P. Overactive bladder syndrome: issues of pathogenesis and diagnosis. Consilium Medicum. Extra Issue 2006; 3.
Romikh V.V., Sivkov A.V. Symptoms of dysfunction of the lower urinary tract: urodynamic aspects. Consilium medicum. Extra Issue 2006;10.
Romikh V.V., Sivkov A.V. Modern aspects of the use of urodynamic studies in urogynecology. Consilium medicum. 2004; 6:7:513–516.
Mazo E.B., Krivoborodov G.G., Shkolnikov M.E. and others. Drug treatment of patients with neurogenic detrusor hyperactivity. RMJ. 2005; 13(9): 619–622.
Krupatkin A.N., Sidorov V.V. Laser Doppler flowmetry of blood microcirculation. Guide for doctors. M.: OJSC “Publishing House “Medicine” 2005;256.
Danilov V.V., Volnykh I.Yu., Danilova T.I. The role of the α-1 adrenergic blocker alfuzosin in the diagnostic and treatment algorithm for the management of women with an overactive bladder and the selection of patients for treatment with M-anticholinergics. Urology. 2005; 1:44–47.
Sivkov A.V., Romikh V.V., Egorov A.A. The use of alpha-blockers for urinary disorders in women. Urology. 2002; 5:52–63.
Nickel J.C. The use of alpha (1)-adrenoreceptor antagonists in lover urinary tract symptoms: beyond beating prostatic hyperplasia. Urology. 2003; 62:34–41.
Pushkar D.Yu., Laurent O.B., Rasner P.I. Experience with drug therapy with Dalfaz in patients with various urinary disorders. Pharmateka. 2005; 11:40.
Robinson S.D., Ludlam C.A., Boon N.A. et al. Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease. Heart. 2006;92(2):170–176.
Reffeimann T., Kloner R.A. Therapeutics Potential of Phosphodiesterase 5 Inhibition for Cardiovascular Disease. Circulation 2003;15:239–244.
Neymark A.I., Kondratieva Yu.S. The role of laser Doppler flowmetry in the assessment of microcirculatory disorders in patients with chronic urethroprostatitis complicated by sexually transmitted infection. Laser medicine. 2007; 11(2): 48–52.
Vishnevsky E.L., Pushkar D.Yu., Laurent O.B. and others. Uroflowmetry. M.: Printed City. 2004; 220.
